2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Motor Activity
14
Breast Neoplasms
11
Polycystic Ovary Syndrome
8
Obesity
8
Colorectal Neoplasms
8
Weight Loss
6
Neoplasms
6
Prostatic Neoplasms
5
Colonic Neoplasms
5
Endometrial Neoplasms
4
Multiple Endocrine Neoplasia Type 1
3
Recurrence
2
Pancreatic Neoplasms
2
Overweight
2
Ovarian Neoplasms
2
Malnutrition
2
Lymphoma, Follicular
2
Lymphoma
2
Lung Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Body Weight Changes
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking Cessation
1
Smoking
1
Sexual Dysfunction, Physiological
1
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recurrence
×
Diet
×
Clear all
NCT07494201
2026-03-27
MIMICC
Fondazione del Piemonte per l'Oncologia
Phase NA
Recruiting
2,500 enrolled
NCT02035631
2014-01-14
PREDICOP
Institut Català d'Oncologia
Phase 3
Unknown
2,000 enrolled